EVAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Evaxion A/S (EVAX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's recent licensing agreement with Merck, positive clinical trial results, and expanding vaccine pipeline provide strong growth potential. Despite weak financial performance in 2025/Q4, the positive news catalysts and analyst rating with a $10 price target make this a compelling long-term investment opportunity.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 61.34, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level of 3.481, suggesting limited immediate upside but potential for long-term growth.
Licensing agreement with Merck for EVX-B3, including a $7.5 million option fee and potential milestone payments of up to $592 million.
Positive clinical trial results for EVX-01 with a 75% objective response rate.
Expansion of vaccine pipeline with EVX-04 and EVX-B
Significant increase in cash and cash equivalents to $23.2 million in 2025.
Revenue dropped to 0 in 2025/Q4, down -100% YoY.
Gross margin dropped to 0, down -100% YoY.
EPS dropped to -0.02, down -93.55% YoY.
In 2025/Q4, revenue dropped to 0 (-100% YoY), but net income improved to -$5.918 million (up 63.08% YoY). EPS dropped to -0.02 (-93.55% YoY), and gross margin fell to 0 (-100% YoY).
Maxim initiated coverage with a Buy rating and a $10 price target, indicating significant upside potential from the current price of $3.4.
